National Taiwan University Hospital (NTUH) has established itself as a global leader in the research and clinical management of Nasopharyngeal Carcinoma (NPC). Through a decades-long cohort study in collaboration with the US National Cancer Institute (NCI) and Academia Sinica, NTUH has validated Epstein-Barr Virus (EBV) antibodies and EBV DNA as highly effective early screening tools, ultimately helping to shape international screening guidelines. Beyond identifying key genetic markers, environmental risk factors, and protective immune responses, NTUH excels in clinical treatment by utilizing advanced induction chemotherapy and minimally invasive salvage surgeries. Consequently, NTUH has achieved an outstanding 5-year survival rate of 78% (significantly outperforming the global average of 62%) and a Stage IV survival rate of 66%, cementing its world-class, comprehensive care model from early high-risk screening to precision medicine.